Patients with Chronic Kidney Disease and End-Stage Renal Disease: Predicting Clinical Outcomes, Healthcare Utilization, and Direct Medical Costs in Relation to Anemia Management and Calcium and Phosphorous Management

Study Details

Patients with Chronic Kidney Disease and End-Stage Renal Disease: Predicting Clinical Outcomes, Healthcare Utilization, and Direct Medical Costs in Relation to Anemia Management and Calcium and Phosphorous Management

David H. Smith, Principal Investigator

This study evaluates secular trends (1997 through 2004) in the age-specific incidence of renal replacement therapy (RRT) for two cohorts: 1) a population-based cohort (i.e., all patients, regardless of an earlier history of chronic kidney disease (CKD), and 2) a clinic-based cohort of patients whose serum creatinine values (i.e., estimated GFRs) preceding the onset of renal replacement therapy could have identified them as suffering from CKD. The study also calculates size and statistical power estimates for a range of excess rates for patients with chronic kidney disease and end-stage renal disease who suffer anemia and, separately, disorders of calcium and phosphorus metabolism.
Funding source: Amgen Inc.

Three Regions — One Mission
Each CHR site conducts professionally independent, public domain research and disseminates its findings in the scholarly literature and scientific community.

Northwest
3800 N. Interstate
Portland, OR 97227
503.335.2400

Hawaii
711 Kapiolani Blvd.
Suite 200
Honolulu, HI 96813
101.222.2400

Southeast
3495 Piedmont Road, NE
Ten Piedmont Center,
Suite 205
Atlanta, GA 30305
202.555.1212

US Map